Roche has no rights to Sovaldi, panel rules

An arbitration panel has ruled that Roche neither holds any patent claims to Gilead HCV drug Sovaldi nor is it entitled to any damages or other relief, Gilead stated in a regulatory filing this past Friday. Roche began the arbitration in 2013, claiming that its 2004 collaboration with Pharmasset—the firm Gilead bought in 2012 and the original owner of Sovaldi—netted the drugmaker a piece of the exclusive rights.